tranexamic acid has been researched along with Hematologic Malignancies in 5 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders." | 9.30 | The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019) |
| "This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders." | 5.30 | The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019) |
| "Among patients with hematologic malignancy undergoing chemotherapy or hematopoietic stem cell transplantation, prophylactic treatment with TXA compared with placebo did not significantly reduce the risk of WHO grade ≥2 bleeding." | 3.11 | Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. ( Boyiadzis, M; Brown, SP; El Kassar, N; Emerson, S; Gernsheimer, TB; Herren, H; Key, NS; May, S; Pagano, MB; Poston, JN; Reeves, BN; Selukar, S; Triulzi, DJ, 2022) |
| "The most robust data for the treatment of menorrhagia are for tranexamic acid." | 2.47 | Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. ( Bates, JS; Buie, LW; Woodis, CB, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gernsheimer, TB | 1 |
| Brown, SP | 1 |
| Triulzi, DJ | 1 |
| Key, NS | 1 |
| El Kassar, N | 1 |
| Herren, H | 1 |
| Poston, JN | 1 |
| Boyiadzis, M | 1 |
| Reeves, BN | 1 |
| Selukar, S | 1 |
| Pagano, MB | 1 |
| Emerson, S | 1 |
| May, S | 1 |
| Zwicker, JI | 1 |
| Estcourt, LJ | 1 |
| McQuilten, Z | 1 |
| Powter, G | 1 |
| Dyer, C | 1 |
| Curnow, E | 1 |
| Wood, EM | 1 |
| Stanworth, SJ | 2 |
| Bates, JS | 1 |
| Buie, LW | 1 |
| Woodis, CB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia[NCT03136445] | Phase 3 | 616 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for tranexamic acid and Hematologic Malignancies
| Article | Year |
|---|---|
Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy.
Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Meno | 2011 |
2 trials available for tranexamic acid and Hematologic Malignancies
| Article | Year |
|---|---|
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Hematologic Neoplasms; Hemorrhage; Huma | 2022 |
The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Australia; Double-Blind | 2019 |
2 other studies available for tranexamic acid and Hematologic Malignancies
| Article | Year |
|---|---|
Tranexamic acid as a stopgap for low platelets?
Topics: Antifibrinolytic Agents; Blood Platelets; Hematologic Neoplasms; Humans; Tranexamic Acid | 2022 |
Use of tranexamic acid in gastrointestinal bleeding and patients with haematological malignancies.
Topics: Antifibrinolytic Agents; Gastrointestinal Hemorrhage; Hematologic Neoplasms; Humans; Tranexamic Acid | 2020 |